- Home
- REAL vs ACIU Comparison
REAL vs ACIU Comparison
Compare REAL & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REAL
- ACIU
- Stock Information
- Founded
- REAL 2011
- ACIU 2003
- Country
- REAL United States
- ACIU Switzerland
- Employees
- REAL N/A
- ACIU N/A
- Industry
- REAL Other Specialty Stores
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- REAL Consumer Discretionary
- ACIU Health Care
- Exchange
- REAL Nasdaq
- ACIU Nasdaq
- Market Cap
- REAL 982.8M
- ACIU 332.4M
- IPO Year
- REAL 2019
- ACIU 2016
- Fundamental
- Price
- REAL $10.99
- ACIU $2.71
- Analyst Decision
- REAL Buy
- ACIU Strong Buy
- Analyst Count
- REAL 6
- ACIU 2
- Target Price
- REAL $7.04
- ACIU $12.00
- AVG Volume (30 Days)
- REAL 3.9M
- ACIU 130.0K
- Earning Date
- REAL 11-04-2024
- ACIU 11-05-2024
- Dividend Yield
- REAL N/A
- ACIU N/A
- EPS Growth
- REAL N/A
- ACIU N/A
- EPS
- REAL N/A
- ACIU N/A
- Revenue
- REAL $579,862,000.00
- ACIU $48,505,404.00
- Revenue This Year
- REAL $11.26
- ACIU $85.33
- Revenue Next Year
- REAL $8.81
- ACIU $80.69
- P/E Ratio
- REAL N/A
- ACIU N/A
- Revenue Growth
- REAL 2.52
- ACIU 4097200.00
- 52 Week Low
- REAL $1.52
- ACIU $2.25
- 52 Week High
- REAL $11.08
- ACIU $5.14
- Technical
- Relative Strength Index (RSI)
- REAL 80.68
- ACIU 29.89
- Support Level
- REAL $9.00
- ACIU $2.62
- Resistance Level
- REAL $9.73
- ACIU $3.07
- Average True Range (ATR)
- REAL 0.84
- ACIU 0.15
- MACD
- REAL 0.07
- ACIU -0.04
- Stochastic Oscillator
- REAL 98.25
- ACIU 17.24
About REAL The RealReal Inc.
The RealReal is the largest pure-play luxury resale platform in the us, generating $1.7 billion in 2023 gross merchandise volume and addressing a niche (personal luxury resale) that had previously been serviced by inefficient upscale boutiques and local pawn shops. The company generates revenue via consignment and first-party sales on its online marketplace, and through a small volume of direct sales. With a hands-on approach that actively sources inventory and authenticates every item on its platform, The RealReal is able to justify much higher take rates than peers, working out to roughly 34% of net merchandise value, which excludes returns, cancellations, and first-party sales.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.